OmniSeq News

OmniSeq, Inc. to Participate in the NCI-MATCH Clinical Trial

BUFFALO, N.Y., July 31, 2018 (GLOBE NEWSWIRE) -- OmniSeq, Inc.® a leading innovator in molecular science, today announced it is participating as a CLIA-certified/accredited laboratory for the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision...

read more

OmniSeq & LabCorp Launch OmniSeq Advance℠ Assay

New test combines both targeted therapy and immune-oncology biomarkers in a single test with 99% actionability, providing benefits for the treatment of patients and the development of new therapies.ASCO, CHICAGO, ILLINOIS – June 1, 2018 – OmniSeq® , a CAP accredited,...

read more

OmniSeq & LabCorp Launch Tumor-Only MSI NGS Assay

BUFFALO, NEW YORK – April 16, 2018 – OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global life sciences company, announced today the commercial launch of OmniSeq MSI NGS, a tumor-only,...

read more

Launch of Immune Report Card

BUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) -- OmniSeq, an innovation of Roswell Park Cancer Institute, announced today the commercial launch of Immune Report Card SM, the first immune profiling test designed to help oncologists select the best mono and...

read more

Follow Us on Twitter

Dr. Sean Glenn speaking in packed house at #SITC2018 on microsatellite instability by (NGS) Next Generation Sequencing.


Grace Dy, M.D. giving her talk at the SITC Immune Escape Program.


Immune Report Card®: New Test Matches Patients With Immunotherapies Likely to Work Best | Roswell Park Comprehensive Cancer Center

Proud that OmniSeq has met the rigorous standards needed to become an NCI-MATCH participating lab. Working hard with our colleagues at LabCorp to bring this testing to NCORP sites across the country!

OmniSeq Advance "All I Want": via @YouTube

Load More...